| Dr Shraddha Prakash, MD | |
|
2500 Merced St, Kaiser Permanente, San Leandro, CA 94577-4201 | |
| (510) 454-5750 | |
| Not Available |
| Full Name | Dr Shraddha Prakash |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 17 Years |
| Location | 2500 Merced St, San Leandro, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053576066 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | A106189 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Highland Hospital | Oakland, CA | Hospital |
| Alameda Hospital | Alameda, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alameda Health System | 3779494521 | 504 |
News Archive
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye.
The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude Children's Research Hospital, Innsbruck Medical University and Max Planck Institute.
There is a unique role for the United States medical community to play in determining the future application of, and ethically acceptable approach to, mitochondrial replacement techniques (MRTs), according to a commentary published online by the New England Journal of Medicine.
› Verified 6 days ago
| Entity Name | Alameda Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740332931 PECOS PAC ID: 3779494521 Enrollment ID: O20031110000764 |
News Archive
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye.
The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude Children's Research Hospital, Innsbruck Medical University and Max Planck Institute.
There is a unique role for the United States medical community to play in determining the future application of, and ethically acceptable approach to, mitochondrial replacement techniques (MRTs), according to a commentary published online by the New England Journal of Medicine.
› Verified 6 days ago
| Entity Name | Healthcare Partners Affiliates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659312593 PECOS PAC ID: 7315842002 Enrollment ID: O20031204001258 |
News Archive
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye.
The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude Children's Research Hospital, Innsbruck Medical University and Max Planck Institute.
There is a unique role for the United States medical community to play in determining the future application of, and ethically acceptable approach to, mitochondrial replacement techniques (MRTs), according to a commentary published online by the New England Journal of Medicine.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shraddha Prakash, MD 2500 Merced St, Kaiser Permanente, San Leandro, CA 94577-4201 Ph: (510) 454-5750 | Dr Shraddha Prakash, MD 2500 Merced St, Kaiser Permanente, San Leandro, CA 94577-4201 Ph: (510) 454-5750 |
News Archive
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye.
The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude Children's Research Hospital, Innsbruck Medical University and Max Planck Institute.
There is a unique role for the United States medical community to play in determining the future application of, and ethically acceptable approach to, mitochondrial replacement techniques (MRTs), according to a commentary published online by the New England Journal of Medicine.
› Verified 6 days ago
Dr. Evelyn Junko Nakagawa, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2800 Benedict Dr, San Leandro, CA 94577 Phone: 415-233-3604 Fax: 415-295-5109 | |
Jeffrey Silvers, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 13847 E 14th St, Suite 116, San Leandro, CA 94578 Phone: 510-895-0388 Fax: 510-895-0342 | |
Dr. Asaf Shor, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Dr. Arlen Randall Hoh, MD, MPH Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 15400 Foothill Blvd, San Leandro, CA 94578 Phone: 510-895-4288 Fax: 510-895-4285 | |
Masood Younus, Rheumatology Medicare: Medicare Enrolled Practice Location: 2500 Merced St Bldg A1, San Leandro, CA 94577 Phone: 510-454-2434 | |
Tri Dang Do, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 101 Callan Ave Ste 300, San Leandro, CA 94577 Phone: 510-300-5340 |